Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E.A. Chong
Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
CTL019 (Tisagenlecleucel): CAR-T Therapy for Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Outcomes of Patients With Large B‐Cell Lymphomas and Progressive Disease Following CD19‐Specific CAR T‐Cell Therapy
American Journal of Hematology
Hematology
Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
MSKCC Early Experience Using Radiotherapy as a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma Before Cd19 Car T Therapy
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rapid Relapse of Large B‐Cell Lymphoma After CD19 Directed CAR‐T‐Cell Therapy Due to CD‐19 Antigen Loss
American Journal of Hematology
Hematology
Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Gemcitabine Plus Liposomal Doxorubicin for Relapsed Refractory T-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
